Dompé’s rhNGF receives orphan drug designation from the EMA

The drug, discovered and developed in Italy, is being studied in patients with neurotrophic keratitis, a pathology still lacking an effective treatment that affects fewer than five out of 10,000 individuals
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Specials orphan drugs Ophthalmology Research cornea eye pathology Latest News neurotrophic keratitis REPARO Phase I/II rhNGF Source Type: news